Hagop Kantarjian joins Actinium Pharmaceuticals’ clinical advisory board

Wednesday, October 3, 2012 09:39 AM

Actinium Pharmaceuticals (API), a New York-based biopharmaceutical company focused on immunotherapeutics, has appointed Hagop Kantarjian, MD, to the company's clinical advisory board. 

Kantarjian, who heads the largest leukemia service in the world at MD Anderson Cancer Center in Houston, Texas, will help API in developing its clinical stage drug candidates in the field of hematologic oncology, Actimab-A and Iomab-B, as well as other earlier stage products.

"[Kantarigian] is one of the foremost blood cancer experts in the world and has achieved many esteemed certifications, honors and awards over his career,” said Jack Talley, CEO of Actinium Pharmaceuticals. “Actinium has assembled a superb team of clinical experts to help guide our programs to their next milestones and ultimately expand the number of patients who are successfully in remission for acute myeloid leukemia or able to have a successful bone marrow transplant due to our product candidates."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs